Changchun BCHT Biotechnology Co. Stock

Equities

688276

CNE100005XY6

Pharmaceuticals

End-of-day quote Shanghai S.E. 18:00:00 2024-06-13 EDT 5-day change 1st Jan Change
31.41 CNY -1.78% Intraday chart for Changchun BCHT Biotechnology Co. +0.83% -42.69%

Financials

Sales 2024 * 2.47B 341M 468M Sales 2025 * 3.02B 417M 572M Capitalization 12.99B 1.79B 2.46B
Net income 2024 * 710M 97.86M 134M Net income 2025 * 931M 128M 176M EV / Sales 2024 * 5.25 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 4.3 x
P/E ratio 2024 *
18.4 x
P/E ratio 2025 *
13.9 x
Employees 1,241
Yield 2024 *
0.98%
Yield 2025 *
1.28%
Free-Float 21.55%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.78%
1 week+0.83%
Current month-7.62%
1 month-19.00%
3 months-41.77%
6 months-44.57%
Current year-42.69%
More quotes
1 week
30.10
Extreme 30.1
32.56
1 month
30.10
Extreme 30.1
39.09
Current year
30.10
Extreme 30.1
58.50
1 year
30.10
Extreme 30.1
68.50
3 years
30.10
Extreme 30.1
135.88
5 years
30.10
Extreme 30.1
135.88
10 years
30.10
Extreme 30.1
135.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 03-12-31
Director of Finance/CFO 60 19-01-31
Chairman 58 04-02-29
Members of the board TitleAgeSince
Director/Board Member 55 04-02-29
Director/Board Member 57 21-08-02
Director/Board Member 60 19-02-20
More insiders
Date Price Change Volume
24-06-14 31.41 -1.78% 3,020,169
24-06-13 31.98 +0.57% 2,932,988
24-06-12 31.8 -1.91% 3,410,151
24-06-11 32.42 +4.08% 4,271,548
24-06-07 31.15 -0.26% 3,268,402

End-of-day quote Shanghai S.E., June 13, 2024

More quotes
Changchun BCHT Biotechnology Co is a China-based innovative biomedical company mainly dedicated to the prevention and treatment of infectious diseases. The Company is mainly engaged in the research and development, production and sales of human vaccines. The Company has three approved vaccine products: varicella vaccine, rabies vaccine and freeze-dried nasal spray flu vaccine. The Company also has other vaccines under development and fully human monoclonal antibody under development for the prevention and control of infectious diseases. The Company mainly conducts business within the domestic market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
31.41 CNY
Average target price
54.56 CNY
Spread / Average Target
+73.72%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688276 Stock